NEW EXPERIENCED MANAGEMENT TO MOVE SWIFTLY ON LICENSING, FUNDING, ACQUISITION AND INFORMATION MANAGEMENT INITIATIVES TO ACCELERATE GROWTH SHANGHAI, China, Feb. 17 /PRNewswire-FirstCall/ -- The Board of Directors of Sinobiomed Inc.

Sinobiomed Inc. ("Sinobiomed", or "the Company") (OTCBB: SOBM) is pleased to announce that it has retained CB Capital Partners, Inc. as its financial advisor to evaluate strategic alternatives to maximize shareholder value.

Sinobiomed, Inc. ("Sinobiomed", or "the Company") (OTCBB: SOBM) is pleased to announce that it has applied for a Chinese and an international patent for recombinant human kallikrein-1 (rhK1), and for a Chinese patent for an innovative recombinant multivalent tuberculosis vaccine.

Sinobiomed, Inc.

Sinobiomed Inc. ("Sinobiomed", or the "Company") (OTCBB: SOBM) is pleased to announce that it is launching the Phase II Clinical Trial of its patented malaria vaccine candidate, PfCP2.9, in epidemic areas in Q3 2008.